Safety of Long-Term Proactive Management With Fixed-Dose Combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam in Patients With Psoriasis Vulgaris: Results of a Phase III, Multicentre, Randomized, 52-Week, Vehicle-Controlled Trial. J of Skin 2020, 4 (5), s31. https://doi.org/10.25251/skin.4.supp.31.